

# Weekly COVID-19 Breakthrough Infections Report

**Clark County, Nevada** 


### Date: January 24, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.


Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.



### Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overall			
A 11	N %			
All Ano (in yours)	129421 10	U		
Age (in years)	-	_		
0-4		0		
5-11		1		
12-17		5		
18-24		9		
25-49	56551 4			
50-64	30826 2			
65+	23466 1	8		
Gender	=			
Male	56420 4			
Female	72027 5			
Unknown	974	1		
Race/Ethnicity				
Hispanic	26659 2			
White	41186 3			
Black		8		
API	16556 1			
AEA		0		
Other		7		
Unknown	25202 1	9		
Travel History				
Yes		4		
No	35283 2			
Unknown	88547 6	8		
Hospitalization				
Yes		3		
No	39811 3	1		
Unknown	86287 6	7		
Death				
Yes		1		
No		8		
Unknown	118366 9	1		
Vaccine Type				
Pfizer	86544 6	7		
Novavax		C		
Unknown		1		
Moderna	34741 2	7		
Janssen	7029	5		
Emergen	1	С		
Underlying Conditions				
Yes	19551 1	5		
No	109870 8	5		

### Table 1: Population Characteristics of COVID-19 Breakthrough Cases

## Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
870607	129421	1447567	467920	14866	32325



Table 3:Population Characteristics of COVID-19 Breakthrough Hospitalizations
--

	Overall
	N %
All	3323 100
Age (in years)	
5-11	5 C
12-17	19 1
18-24	33 1
25-49	339 10
50-64	579 17
65+	2348 71
Gender	
Male	1808 54
Female	1511 45
Unknown	4 C
Race/Ethnicity	
Hispanic	415 12
White	1936 58
Black	373 11
API	326 10
AEA	16 C
Other	100 3
Unknown	157 5
Travel History	
Yes	142 4
No	1714 52
Unknown	1467 44
Death	
Yes	846 25
No	589 18
Unknown	1888 57
Vaccine Type	
Pfizer	1935 58
Unknown	82 2
Moderna	1057 32
Janssen	249 7
Underlying Conditions	
Yes	2400 72
No	923 28



	Over	Overall	
	Ν	%	
All	1199	100	
Age (in years)			
25-49	37	3	
50-64	146	12	
65+	1016	85	
Gender			
Male	721	60	
Female	478	40	
Race/Ethnicity			
Hispanic	130	11	
White	809	67	
Black	126	11	
API	114	10	
AEA	6	1	
Other	10	1	
Unknown	4	0	
Hospitalization			
Yes	846	71	
No	75	6	
Unknown	278	23	
Vaccine Type			
Pfizer	659	55	
Unknown	27	2	
Moderna	391	33	
Janssen	122	10	
Underlying Conditions			
Yes	687	57	
No	512	43	

### Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

### **Table 5: Breakthrough Death Rates**

Fully Vaccinated	Vaccinated	Unvaccinated	Unvaccinated	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate
Population	Deaths	Population	Deaths		per 100K population
870607	1199	1447567	8085	138	559

\* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	2400	72
	No	923	28
Hypertension	Yes	1534	N/A
Immunocompromised	Yes	134	N/A
Chronic Heart Disease	Yes	723	N/A
Chronic Liver Disease	Yes	62	N/A
Chronic Kidney Disease	Yes	474	N/A
Diabetes	Yes	901	N/A
Neurologic/Neurodevelopmental	Yes	198	N/A
Chronic Lung Disease	Yes	633	N/A
Historically Healthy	Yes	291	N/A

### Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

#### Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	687	57
	No	512	43
Hypertension	Yes	442	N/A
Immunocompromised	Yes	50	N/A
Chronic Heart Disease	Yes	247	N/A
Chronic Liver Disease	Yes	24	N/A
Chronic Kidney Disease	Yes	188	N/A
Diabetes	Yes	262	N/A
Neurologic/Neurodevelopmental	Yes	60	N/A
Chronic Lung Disease	Yes	199	N/A
Historically Healthy	Yes	26	N/A

Notes:

\* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

\* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

\* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).